← Leaderboards
Penelope Jane Hallett
Mclean Hospital
$5,641,169
Attributed
$15,584,892
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2015–24$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$15,584,892 · 4
By mechanism
U01$9,168,144 · 1
R01$4,132,452 · 2
RF1$2,284,296 · 1
Top collaborators
- Ole Isacson13 shared
- James M Schumacher7 shared
- Michelle L Hastings5 shared
- Oliver Cooper4 shared
- Anna Charlotta Teresia Magnuson Osborn3 shared
Most similar at Mclean Hospital
Same institution · by research overlap
- Ole Isacson$16,866,444
- James M Schumacher$2,292,036
- Oliver Cooper$1,431,036
- Sangmi Chung$8,912,133
- Anna Charlotta Teresia Magnuson Osborn$861,000
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainSynapsesExperimental StudyInduced Pluripotent Stem CellParkinson DiseaseCellsAlzheimer&AposMidbrain StructureNeuronsDopaminergic NeuronParkinsonian DisordersNeurodegenerative DisordersNerve DegenerationIn VitroFunctional DisorderPathologyS DiseaseDisease ModelDesignMutationAlpha SynucleinIn Vitro TestingIn VivoGlycosphingolipids
Grant awards (17)
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,958,850
U01 · FY2024 · NS · contact PI
ApoE, lipid and immune mechanisms of human neurons and glia$2,284,296
RF1 · FY2023 · AG
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,961,294
U01 · FY2023 · NS · contact PI
Parkinsons disease scalable iPSC autologous cell therapy$164,000
U01 · FY2023 · NS · contact PI
Parkinsons Disease Scalable iPSC Autologous Cell Therapy$1,640,000
U01 · FY2022 · NS · contact PI
Prevention of complement and immune-mediated Lewy body dementia$563,846
R01 · FY2022 · AG
Parkinsons disease scalable iPSC autologous cell therapy$164,000
U01 · FY2022 · NS · contact PI
Parkinsons disease scalable iPSC autologous cell therapy$1,640,000
U01 · FY2021 · NS · contact PI
Prevention of complement and immune-mediated Lewy body dementia$569,300
R01 · FY2021 · AG
Parkinsons disease scalable iPSC autologous cell therapy$1,640,000
U01 · FY2020 · NS · contact PI
Prevention of complement and immune-mediated Lewy body dementia$574,594
R01 · FY2020 · AG
Prevention of complement and immune-mediated Lewy body dementia$579,735
R01 · FY2019 · AG
Prevention of complement and immune-mediated Lewy body dementia$600,725
R01 · FY2018 · AG
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2018 · NS · contact PI
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2017 · NS · contact PI
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2016 · NS · contact PI
Critical analysis of glycosphingolipid pathways in aging and Parkinsons disease$311,063
R01 · FY2015 · NS · contact PI